H

ello, everyone, and how are you today? We are just fine, thank you, despite daunting weather that altered travel plans. Nonetheless, we managed to arrive at the JP Morgan health care fest, albeit not as soon as we hoped, and plan to scurry about meeting interesting people. As we indicated previously, this will call for sporadic posting. Nonetheless, we have assembled the usual menu of tidbits. We will now search for a cup of stimulation. Have a grand day and do keep in touch …

Johnson & Johnson is set to issue a report next month outlining how much it has raised US prices for its prescription drugs, the Wall Street Journal writes. The report will provide the average increase in list prices, as well as average prices after the discounts given by the health care giant. But J&J is not pledging to hold price hikes to single-digit increases, because the company maintains it already does so.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.